Hypothesis: The potential utility of topical eflornithine against cutaneous leishmaniasis

Indian Journal of Dermatology, Venereology and Leprology

Volumn 74, Issue 2, 2008, Pages 158-159

  Namazi, M ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; MEGLUMINE ANTIMONATE; ORNITHINE DECARBOXYLASE;

AFRICAN TRYPANOSOMIASIS; DRUG MECHANISM; HAIR LOSS; HUMAN; HYPERACTIVITY; LEISHMANIA; LETTER; NONHUMAN; SKIN LEISHMANIASIS;

EID: 42049112064     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.39709     Document Type: Letter

References (7)

1. Kapoor P, Sachdev M, Madhubala R. Inhibition of glutathione synthesis as a chemotherapeutic strategy for leishmaniasis. Trop Med Int Health 2000;5:438-42.
2. Haimeur A, Guimond C, Pilote S, Mukhopadhyay R, Rosen BP, Poulin R, et al. Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol Microbiol 1999;34:726-35.
3. Reguera RM, Fouce RB, Cubria JC, Bujidos ML, Ordonez D. Fluorinated analogues of L-ornithine are powerful inhibitors of ornithine decarboxylase and cell growth of Leishmania infantum promastigotes. Life Sci 1995;56:223-30.
4. th ed, Vol.4, London: Blackwell Science; Chapter 63, 2004. p. 63.106
5. Jobanputra KS, Rajpal AV, Nagpur NG. Eflornithine. Indian J Dermatol Venereol Leprol 2007;73:365-6.
6. Powell P, Lucas K. Vaniqa (eflornithine hydrochloride). New Drug Update 2002;8:3.
7. Coyne P. The eflornithine story. J Am Acad Dermatol 2001;45:784-6.